StockMarketNewsAlert.com Issues New Trade Alert for Dynavax Technologies


BOCA RATON, Fla., Nov. 29, 2006 (PRIME NEWSWIRE) -- StockMarketNewsAlert.com issues a New Trade Alert for Dynavax Technologies (Nasdaq:DVAX). According to M. D'Alonzo at First Equity Group Inc., recent news flow from the company has been very positive: "Dynavax Technologies Corporation announced statistically significant results from the primary endpoint analysis of a Phase 3 trial comparing HEPLISAV, its hepatitis B virus (HBV) vaccine, to GlaxoSmithKline's Engerix-B(r) vaccine in a difficult-to-immunize population of older adults. The primary endpoint is seroprotection four weeks after the third immunization. The Company announced today that it has secured a contract totaling approximately $1.0 million from a leading Midwestern utility customer to provide SCR catalyst regeneration services."

The data show that after three doses, HEPLISAV provided seroprotection to 100% of subjects versus 73.1% for Engerix-B. The greatest difference in seroprotection after three doses was seen in subjects 56 to 70 years of age where HEPLISAV provided 100% seroprotection and Engerix-B provided 56.1%. Data for the entire study population show that after two doses, HEPLISAV provided 98.5% seroprotection versus Engerix-B's 25%. Furthermore, HEPLISAV provided a level of immunity as measured by geometric mean concentrations of anti-HBsAg antibodies 18.5 times higher than Engerix-B four weeks after the third dose.

About Dynavax

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative TLR9 agonist-based products to treat and prevent allergies, infectious diseases, cancer, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our TLR9 agonists are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Our pipeline includes: TOLAMBA(tm), a ragweed allergy immunotherapeutic, for which a major safety and efficacy trial (DARTT) is currently underway, and that is in a supportive clinical trial in ragweed allergic children; HEPLISAV(tm), a hepatitis B vaccine in Phase 3; and a therapy for non-Hodgkin's lymphoma in Phase 2. Our pre-clinical asthma and COPD programs are partnered with AstraZeneca. Funding for our other preclinical programs in cancer, hepatitis B and hepatitis C therapies, and for an influenza vaccine has been provided by Symphony Dynamo, Inc. and the NIH, and these programs represent future partnering opportunities. For more information, please visit www.dynavax.com.

Safe Harbor Statement

This press release contains forward-looking statements that are subject to a number of risks and uncertainties, including statements about the potential safety and efficacy of HEPLISAV, whether successful results may be shown in additional clinical studies, whether HEPLISAV may show similar or supportive results in the upcoming Phase 3 clinical studies and the potential for HEPLISAV to achieve clinical and commercial success. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in our business, including difficulties or delays in development, achieving the objectives of our collaborative and licensing agreements and obtaining regulatory approval for our products; the scope and validity of patent protection for our products; possible claims against us on the patent rights of others; competition from other companies; our ability to obtain additional financing to support our operations; and other risks detailed in the 'Risk Factors' section of our Annual Report on Form 10-K and Quarterly Report on Form 10-Q. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

About StockMarketNewsAlert.com

StockMarketNewsAlert.com was developed solely for experienced, risk-tolerant investors. Subscribers to StockMarketNewsAlert.com receive daily market commentary reports for select companies trading on various markets. Sophisticated investors are also able to receive for free, select, rare research reports and investor kits on up and coming emerging companies while they are still not widely known.

StockMarketNewsAlert.com's (SMNA) primary focus is promoting awareness among brokers, investors, and others in the investment community who are interested in small- and micro-cap companies. StockMarketNewsAlert.com is dedicated to helping publicly traded companies gain the exposure they need to move forward with the development of their business plans. SMNA's goal is to feature equity investments in micro- or small-capitalization companies that have the potential for long-term appreciation. SMNA provides investors with a complete suite of online interactive financial data and tools that includes quotes, charts, company profiles, news, market commentary and SEC filings, just to name a few. Stockmarketnewsalert.com offers a free financial newsletter. To subscribe or get more information, visit our home page located at www.stockmarketnewsalert.com.

Let Stock Market News Alert help advertise for your company using our effective awareness campaigns. If you're interested in telling your story, we can help. Contact us at info@stockmarketnewsalert.com. SMNA's e-mail alert service is free to those investors who sign up on the SMNA home page. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to Special Situation companies that have the potential of showing increased activity. To subscribe to this free service, visit the Stock Market News Alert home page at http://www.stockmarketnewsalert.com and select the "sign up" button.

Information contained herein is the opinion of stockmarketnewsalert.com and is intended to be used strictly for informational purposes. You should be aware that SMNA attempts to assure itself of the accuracy of the information contained in the analyses it publishes. In this regard, SMNA does, at times, rely on the accuracy of information supplied to it by the companies, which are the subject of SMNA's analyses and/or parties related to those companies. SMNA also relies on the accuracy and integrity of information that is contained in company press releases and reports filed with the SEC. The companies mentioned in this publication have not approved the content or timing of the information being published unless otherwise noted.

SMNA, because it relies on information supplied by various third parties, disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of a SMNA analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an SMNA opinion, recommendation or analysis.

Information regarding companies, which SMNA has an opinion upon, is normally available from many sources including the subject company's filings with the SEC and various press releases issued by the company.

All material herein is information supplied by the company or other sources believed to be reliable. The information contained herein is not guaranteed by First Equity Group, Inc. to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this profile have approved the statements made in this profile. This profile contains forward-looking statements that involve risks and uncertainties. Statements in this press release about the company's future expectations other than historical facts, are "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Act of 1934, as that term is defined in the Private Securities Litigation Reform Act of 1995. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements. Such "forward-looking statements" are subject to risks and uncertainties set forth from time to time in the company's SEC reports that could cause results to differ materially from those expressed or implied include, but are not limited to, the results of future tests and the availability of funding for additional research and development. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. First Equity Group is not a licensed broker, broker dealer, market maker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.stockmarketnewsalert.com. First Equity Group may have purchased shares in a private placement or on the open market. First Equity Group's affiliates, officers, directors, and employees may also have bought or may buy the shares discussed in this profile and may profit in the event those shares rise in value. First Equity Group does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.



            

Coordonnées